• Home
  • About
    • About Us
    • Executive Team
    • Board of Directors
    • Scientific Advisory Board
  • Pipeline
    • Overview
    • PAS-004
    • NF1
    • Presentations & Publications
  • Patients
    • Clinical Trials
    • Expanded Access
  • Investors
  • Contact

Pasithea Therapeutics Launches In-Home Intravenous Ketamine Therapy in Major U.S. Cities, Expanding its International Footprint

by divibasicbldev | Nov 17, 2021 | Press Releases

— Pasithea Clinics to offer ketamine infusion therapy for the treatment of mental health disorders — — First mobile clinics launch in New York City, Los Angeles, San Diego, and San Francisco, with expansion to additional U.S. cities in coming months...

Pasithea Therapeutics Collaborates with Renowned Musician and Producer to Create Soundtracks for Ketamine Therapy

by divibasicbldev | Nov 11, 2021 | Press Releases

— Music plays an important role in ketamine therapy and is known to facilitate positive outcomes –MIAMI BEACH, Fla., Nov. 11, 2021 (GLOBE NEWSWIRE) — Pasithea Therapeutics Corp. (Nasdaq: KTTA) (Pasithea or the Company), a novel biotechnology company...

Pasithea Therapeutics Corp. Establishes Scientific Advisory Board and Names Dr. Charles B. Nemeroff as Chair

by divibasicbldev | Nov 9, 2021 | Press Releases

Newly formed SAB to provide direction as company advances mission to develop improved treatments for mental health and brain disordersMIAMI BEACH, Fla., Nov. 09, 2021 (GLOBE NEWSWIRE) — Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the...

Pasithea Therapeutics Announces Successful Treatment of First Patients in the UK with Ketamine Infusion Therapy

by divibasicbldev | Oct 27, 2021 | Press Releases

– Pasithea Clinics commences IV ketamine infusion therapy in Knightsbridge, London, for the treatment of mental health disorders -MIAMI BEACH, Fla., Oct. 27, 2021 (GLOBE NEWSWIRE) — Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the...

Pasithea Therapeutics Opens its First Ketamine Therapy Clinic in the United Kingdom

by divibasicbldev | Oct 14, 2021 | Press Releases

— Pasithea Clinics partners with ZEN Healthcare – a network of health clinics in Central London – to offer ketamine infusion therapy for the treatment of mental health disorders — — Ketamine in sub-anesthetic doses has shown to be highly...

Pasithea Therapeutics Corp. and Evotec SE Enter into Drug Development Agreement

by divibasicbldev | Oct 11, 2021 | Press Releases

— Company contracts leading global drug development company to advance initial drug candidate –MIAMI BEACH, Fla., Oct. 11, 2021 (GLOBE NEWSWIRE) — Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a...
« Older Entries
Next Entries »

Recent Posts

  • Pasithea Therapeutics Announces Presentation of Initial PAS-004 Clinical Data from Ongoing Phase 1/1b Clinical Trial in Adult NF1 Patients at the 2026 European Neurofibromatosis Conference
  • Pasithea Therapeutics Announces Participation in Two September 2026 Investor Conferences
  • Pasithea Therapeutics Announces Presentation of PAS-004 Data to European Society for Medical Oncology (ESMO) Congress 2026
  • Pasithea Therapeutics Announces Participation in B. Riley Securities Mind, Muscle & Vision Summit
  • Pasithea Therapeutics Announces Positive Interim Phase 1 Advanced Cancer Study Data Demonstrating Long-Term Safety and Tolerability, and Durable Clinical Activity in MEK/BRAF-Pretreated Patients, plus Protocol Expansion

Recent Comments

No comments to show.
Email Alerts

© Pasithea Therapeutics Corp. All Rights Reserved.